Investigating the Neural Signature of Freezing of Gait in Parkinson's Disease
Launched by KU LEUVEN · Feb 18, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Clinical diagnosis of Parkinson's disease (PD) made by a Neurologist\*
- • 2. Modified Hoehn \& Yahr (H\&Y) Stage I to IV in the ON medication state
- • 3. Age above 18 years\*
- • 4. Able to walk 5 minutes while unassisted by a walker or another person (the use of a cane is allowed).\*
- • 5. Mini Mental State Examination\>= 21
- • 6. At least three hours in-between regular medication intakes to allow for stable testing time.\*
- • 7. Self-reported FOG with a severity of at least 1 FOG episode per day, based on items 1 and 2 of the New Freezing of Gait Questionnaire, irrespective of FOG occurring ON- or OFF-medication.\*
- • 8. Stable medication scheme for at least 7 days before enrollment.
- Exclusion Criteria:
- • 1. Participation in another clinical intervention study\*
- • 2. Acute musculoskeletal or other neurological, psychiatric, or cardiovascular conditions affecting gait or any other medical condition which, in the opinion of the investigator, may prevent the participant from completing the protocol in full
- • 3. Unable to adhere to assessment procedures leading to missing or unusable data, as determined by the investigators
- • 4. Not a stable medication scheme for at least 7 days before the assessment.\*
- 5. Occurrence of any of the following within 3 months prior to informed consent:
- • Orthopedic surgery of the lower extremity
- • Myocardial infarction
- • Hospitalization for unstable angina
- • Coronary artery bypass graft
- • Percutaneous coronary intervention
- • Implantation of a cardiac resynchronization therapy device
- • Implantation of deep brain stimulation
- • 6. Substance abuse that may interfere with the patient's compliance
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Trial Officials
Moran Gilat, PhD
Principal Investigator
KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported